Which class of drugs inhibits the reuptake of serotonin from the synapses?

Selective Serotonin Reuptake Inhibitors (SSRIs) are specifically designed to target the serotonin system by inhibiting the reuptake of serotonin from the synaptic cleft back into the presynaptic neuron. This action increases the concentration of serotonin available in the synapses, enhancing serotonergic transmission, which is beneficial in treating depression and anxiety disorders.

The primary mechanism of SSRIs involves blocking the serotonin transporter (SERT), which is responsible for the reabsorption of serotonin after its release. By preventing this reuptake, SSRIs effectively increase the level of serotonin active at the receptor sites, leading to improved mood and emotional regulation.

Other classes of drugs mentioned, such as Monoamine Oxidase Inhibitors (MAOs), Tricyclic antidepressants, and Norepinephrine and dopamine reuptake inhibitors (NDRIs), have different mechanisms of action. MAOs function by inhibiting the enzyme responsible for breaking down monoamines, thus increasing levels of these neurotransmitters but not specifically targeting reuptake. Tricyclic antidepressants impact various neurotransmitter systems, affecting both norepinephrine and serotonin reuptake but are not as selective as SSRIs. NDRIs primarily inhibit the reuptake of